WANY
UTHR icon

Wealthspire Advisors (New York)’s United Therapeutics UTHR Stock Holding History

Wealthspire Advisors (New York)’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-832
Closed -$405K – 1098
2025
Q4 		$405K Buy
832
+719
+636% +$335K ﹤0.01% 684
2025
Q3 		$47.4K Buy
+113
New +$38K ﹤0.01% 1272

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Wealthspire Advisors (New York)'s UTHR Position: Q1 2026 in Review

Wealthspire Advisors (New York) sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 832 shares — an estimated $405K sold.

Wealthspire Advisors (New York) first reported a position in UTHR in Q3 2025 and held it in 2 quarters. The position peaked at $405K in Q4 2025. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Wealthspire Advisors (New York) reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 832 United Therapeutics shares in Q1 2026, an estimated $405K.
  • Wealthspire Advisors (New York) first reported a position in United Therapeutics in Q3 2025 and held it in 2 quarters.
  • Wealthspire Advisors (New York)'s United Therapeutics position peaked at $405K in Q4 2025.
  • 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.